ZSCAN10

Summary

ZSCAN10 (zinc finger and SCAN domain containing 10, HGNC:12997) is a protein-coding gene on chromosome 16p13.3, encoding Zinc finger and SCAN domain-containing protein 10 (Q96SZ4). Embryonic stem (ES) cell-specific transcription factor required to maintain ES cell pluripotency.

Predicted to enable DNA-binding transcription factor activity, RNA polymerase II-specific and RNA polymerase II cis-regulatory region sequence-specific DNA binding activity. Predicted to be involved in negative regulation of DNA-templated transcription and regulation of transcription by RNA polymerase II. Predicted to be located in nucleoplasm. Predicted to be active in nucleus.

Source: NCBI Gene 84891 — RefSeq curated summary.

At a glance

• Gene–disease (curated): otofacial neurodevelopmental syndrome (Strong, GenCC)
• Clinical variants (ClinVar): 165 total — 5 pathogenic
• Phenotypes (HPO): 33
• MANE Select transcript: NM_032805

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:12997
Approved symbol	ZSCAN10
Name	zinc finger and SCAN domain containing 10
Location	16p13.3
Locus type	gene with protein product
Status	Approved
Ensembl gene	ENSG00000130182
Ensembl biotype	protein_coding
OMIM	618365
Entrez	84891

Gene structure

Transcript identifiers

Ensembl transcripts: 10 — 7 protein_coding, 2 retained_intron, 1 protein_coding_CDS_not_defined

ENST00000252463, ENST00000538082, ENST00000571903, ENST00000572431, ENST00000572548, ENST00000573931, ENST00000575108, ENST00000576483, ENST00000576985, ENST00000577059

RefSeq mRNA: 5 — MANE Select: NM_032805 NM_001282415, NM_001282416, NM_001365272, NM_001365273, NM_032805

CCDS: CCDS10493, CCDS61813, CCDS61814

Canonical transcript exons

ENST00000576985 — 6 exons

Exon	Start	End
ENSE00002665101	3088890	3090646
ENSE00002680268	3099190	3099294
ENSE00003484450	3092049	3092316
ENSE00003522626	3091764	3091828
ENSE00003551682	3092542	3093004
ENSE00003629100	3091540	3091597

Expression profiles

Bgee: expression breadth broad, 75 present calls, max score 69.13.

FANTOM5 (CAGE): breadth tissue_specific, TPM avg 1.8688 / max 128.7825, expressed in 113 samples.

FANTOM5 promoters (2 alternative TSS)

Promoter ID	TPM avg	Samples expressed
156009	1.7915	113
156008	0.0773	44

Top tissues by expression

219 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
primordial germ cell in gonad	CL:0000670 ∩ UBERON:0000991	69.13	gold quality
cerebellar vermis	UBERON:0004720	59.11	gold quality
bone marrow cell	CL:0002092	52.69	gold quality
colonic epithelium	UBERON:0000397	50.30	gold quality
cerebellar cortex	UBERON:0002129	49.09	gold quality
cerebellar hemisphere	UBERON:0002245	49.00	gold quality
skin of hip	UBERON:0001554	48.57	silver quality
cerebellum	UBERON:0002037	48.50	gold quality
right hemisphere of cerebellum	UBERON:0014890	47.67	gold quality
hindlimb stylopod muscle	UBERON:0004252	46.76	silver quality
upper leg skin	UBERON:0004262	45.48	silver quality
thymus	UBERON:0002370	45.07	gold quality
gastrocnemius	UBERON:0001388	44.92	gold quality
granulocyte	CL:0000094	44.54	silver quality
ventricular zone	UBERON:0003053	44.33	silver quality
blood	UBERON:0000178	44.28	gold quality
muscle of leg	UBERON:0001383	43.98	gold quality
sural nerve	UBERON:0015488	43.51	gold quality
skeletal muscle tissue of rectus abdominis	UBERON:0004511	43.37	gold quality
quadriceps femoris	UBERON:0001377	43.28	gold quality
bone marrow	UBERON:0002371	42.99	gold quality
epithelium of nasopharynx	UBERON:0001951	42.59	gold quality
secondary oocyte	CL:0000655	42.57	gold quality
vastus lateralis	UBERON:0001379	41.41	gold quality
superficial temporal artery	UBERON:0001614	41.33	gold quality
palpebral conjunctiva	UBERON:0001812	41.10	gold quality
medial globus pallidus	UBERON:0002477	41.10	gold quality
mucosa of paranasal sinus	UBERON:0005030	40.98	gold quality
amniotic fluid	UBERON:0000173	40.69	gold quality
globus pallidus	UBERON:0001875	40.69	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	2.62
E-MTAB-7008	no	211.50

Regulation

Is transcription factor: yes

Downstream targets (CollecTRI)

3 targets.

Target	Regulation
NANOG	Activation
POU5F1	Unknown
ZSCAN10

Upstream regulators (CollecTRI, top): POU5F1, SOX2, ZSCAN10

miRNA regulators (miRDB)

12 targeting ZSCAN10, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-4533	100.00	69.48	2758
HSA-MIR-4747-5P	100.00	67.90	2681
HSA-MIR-5196-5P	100.00	67.98	2761
HSA-MIR-4455	100.00	65.48	1587
HSA-MIR-4493	99.90	66.48	977
HSA-MIR-3202	99.66	67.70	2737
HSA-MIR-12131	99.48	68.72	1673
HSA-MIR-4796-3P	99.08	68.38	1681
HSA-MIR-9500	98.62	66.54	1845
HSA-MIR-6815-5P	96.05	65.55	662
HSA-MIR-6865-5P	96.05	65.58	675
HSA-MIR-4750-5P	80.79	59.79	18

Literature-anchored findings (GeneRIF, showing 4)

• Data indicates that changes in DNA methylation levels at the Zfp206-exon 5 might be one of the important factors during neuronal development in mice and the hypomethylation of the homologous region induced ZNF206 expression in humans. (PMID:22011711)
• We demonstrated that SLC16A5 and ZNF206 displayed altered methylation patterns in the neuroblastoma genome (PMID:22911660)
• The pluripotency factor ZSCAN10 is poorly expressed in A-iPSCs and addition of ZSCAN10 to the four Yamanaka factors (OCT4, SOX2, KLF4 and c-MYC) during A-iPSC reprogramming normalizes ROS-glutathione homeostasis and the DNA damage response, and recovers genomic stability. (PMID:28846095)
• ZSCAN10 deficiency causes a neurodevelopmental disorder with characteristic oto-facial malformations. (PMID:38386308)

Cross-species orthologs

2 orthologs

Organism	Symbol	Gene ID
mus_musculus	Zscan10	ENSMUSG00000023902
rattus_norvegicus	Zscan10	ENSRNOG00000021782

Paralogs (176): ZNF195 (ENSG00000005801), ZNF112 (ENSG00000062370), ZNF275 (ENSG00000063587), ZNF37A (ENSG00000075407), ZNF510 (ENSG00000081386), ZNF506 (ENSG00000081665), ZNF268 (ENSG00000090612), MZF1 (ENSG00000099326), ZNF629 (ENSG00000102870), ZNF175 (ENSG00000105497), ZNF85 (ENSG00000105750), ZFP30 (ENSG00000120784), ZNF45 (ENSG00000124459), ZNF391 (ENSG00000124613), ZNF436 (ENSG00000125945), ZNF484 (ENSG00000127081), ZNF835 (ENSG00000127903), ZNF780B (ENSG00000128000), ZNF317 (ENSG00000130803), ZNF331 (ENSG00000130844), ZNF227 (ENSG00000131115), ZNF141 (ENSG00000131127), ZNF132 (ENSG00000131849), ZNF189 (ENSG00000136870), ZIM3 (ENSG00000141946), ZFP14 (ENSG00000142065), ZNF514 (ENSG00000144026), ZNF300 (ENSG00000145908), RBAK (ENSG00000146587), ZNF157 (ENSG00000147117), ZNF182 (ENSG00000147118), ZNF41 (ENSG00000147124), ZNF7 (ENSG00000147789), ZNF117 (ENSG00000152926), ZNF221 (ENSG00000159905), ZNF235 (ENSG00000159917), ZNF714 (ENSG00000160352), ZNF577 (ENSG00000161551), ZNF12 (ENSG00000164631), ZNF3 (ENSG00000166526)

Protein

Protein identifiers

Zinc finger and SCAN domain-containing protein 10 — Q96SZ4 (reviewed: Q96SZ4)

Alternative names: Zinc finger protein 206

All UniProt accessions (5): Q96SZ4, A0A5P9VN71, I3L0Q3, I3L1J3, I3NI43

UniProt curated annotations — full annotation on UniProt →

Function. Embryonic stem (ES) cell-specific transcription factor required to maintain ES cell pluripotency. Can both activate and /or repress expression of target genes, depending on the context. Specifically binds the 5’-[GA]CGCNNGCG[CT]-3’ DNA consensus sequence. Regulates expression of POU5F1/OCT4, ZSCAN4 and ALYREF/THOC4.

Subunit / interactions. Interacts with POU5F1/OCT4 and SOX2.

Subcellular location. Nucleus.

Post-translational modifications. Methylated at Gln-483 by N6AMT1.

Disease relevance. Otofacial neurodevelopmental syndrome (OFNS) [MIM:620910] An autosomal recessive disorder characterized by mild to severe cognitive impairment, delayed or absent speech development, and behavioral abnormalities. Affected individuals have outer and inner ear malformations, hearing impairment, and variable facial asymmetry. The disease is caused by variants affecting the gene represented in this entry.

Isoforms (3)

UniProt ID	Names	Canonical?
Q96SZ4-1	1	yes
Q96SZ4-2	2
Q96SZ4-3	3

RefSeq proteins (5): NP_001269344, NP_001269345, NP_001352201, NP_001352202, NP_116194* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR003309	SCAN_dom	Domain
IPR013087	Znf_C2H2_type	Domain
IPR036236	Znf_C2H2_sf	Homologous_superfamily
IPR038269	SCAN_sf	Homologous_superfamily

Pfam: PF00096, PF02023

UniProt features (34 total): zinc finger region 14, region of interest 4, compositionally biased region 4, modified residue 4, splice variant 3, sequence variant 2, chain 1, domain 1, mutagenesis site 1

Structure

Experimental structures (PDB)

1 structures.

PDB	Method	Resolution (Å)
9L0V	X-RAY DIFFRACTION	2

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-Q96SZ4-F1	66.12	0.05

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Post-translational modifications (4): 162, 208, 268, 483

Mutagenesis-validated functional residues (1):

Position	Phenotype
483	abolishes methylation by n6amt1.

Function

Pathways and Gene Ontology

Reactome pathways

1 pathways

ID	Pathway
R-HSA-452723	Transcriptional regulation of pluripotent stem cells

MSigDB gene sets: 97 (showing top): HAMAI_APOPTOSIS_VIA_TRAIL_DN, NIKOLSKY_BREAST_CANCER_16P13_AMPLICON, BENPORATH_ES_1, GSE13762_CTRL_VS_125_VITAMIND_DAY5_DC_DN, GOMF_SEQUENCE_SPECIFIC_DNA_BINDING, MIKKELSEN_ES_ICP_WITH_H3K4ME3, GOBP_NEGATIVE_REGULATION_OF_NUCLEOBASE_CONTAINING_COMPOUND_METABOLIC_PROCESS, RAO_BOUND_BY_SALL4, REACTOME_TRANSCRIPTIONAL_REGULATION_OF_PLURIPOTENT_STEM_CELLS, GOMF_TRANSCRIPTION_REGULATOR_ACTIVITY, SALL4_TARGET_GENES, ZNF274_TARGET_GENES, GSE11924_TH1_VS_TH2_CD4_TCELL_UP, GSE13229_IMM_VS_MATURE_NKCELL_UP, HP_CRYPTORCHIDISM

GO Biological Process (2): regulation of transcription by RNA polymerase II (GO:0006357), negative regulation of DNA-templated transcription (GO:0045892)

GO Molecular Function (8): RNA polymerase II cis-regulatory region sequence-specific DNA binding (GO:0000978), DNA-binding transcription factor activity, RNA polymerase II-specific (GO:0000981), DNA-binding transcription factor activity (GO:0003700), zinc ion binding (GO:0008270), sequence-specific DNA binding (GO:0043565), DNA binding (GO:0003677), protein binding (GO:0005515), metal ion binding (GO:0046872)

GO Cellular Component (2): nucleus (GO:0005634), nucleoplasm (GO:0005654)

Reactome top-level categories

Rollup of top-1 pathways:

Category	Pathways
Developmental Biology	1

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
regulation of DNA-templated transcription	3
RNA polymerase II transcription regulatory region sequence-specific DNA binding	2
transcription by RNA polymerase II	1
DNA-templated transcription	1
negative regulation of RNA biosynthetic process	1
cis-regulatory region sequence-specific DNA binding	1
chromatin	1
DNA-binding transcription factor activity	1
regulation of transcription by RNA polymerase II	1
transcription cis-regulatory region binding	1
transcription regulator activity	1
transition metal ion binding	1
DNA binding	1
nucleic acid binding	1
binding	1
cation binding	1
intracellular membrane-bounded organelle	1
nuclear lumen	1
cellular anatomical structure	1

Protein interactions and networks

STRING

688 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
ZSCAN10	POU5F1	P31359	482
ZSCAN10	NANOG	Q9H9S0	480
ZSCAN10	ESRRB	O95718	452
ZSCAN10	SOX2	P48431	451
ZSCAN10	UTF1	Q5T230	448
ZSCAN10	DPPA4	Q7L190	447
ZSCAN10	LIN28A	Q9H9Z2	417
ZSCAN10	CRIPTO	P13385	389
ZSCAN10	VRTN	Q9H8Y1	384
ZSCAN10	GATA6	P78327	378
ZSCAN10	POGZ	Q7Z3K3	378
ZSCAN10	DPPA3	Q6W0C5	370
ZSCAN10	CCDC120	Q96HB5	367
ZSCAN10	TFAP2A	P05549	362
ZSCAN10	ZBTB21	Q9ULJ3	354
ZSCAN10	GDF3	Q9NR23	354

IntAct

4 interactions, top by confidence:

A	B	Type	Score
KRTAP10-7	ZSCAN10	psi-mi:“MI:0915”(physical association)	0.560
ZSCAN10	KRTAP10-7	psi-mi:“MI:0915”(physical association)	0.000

BioGRID (4): ZSCAN10 (Affinity Capture-MS), ZSCAN10 (Affinity Capture-MS), KRTAP10-7 (Two-hybrid), ZSCAN10 (Proximity Label-MS)

ESM2 similar proteins: A0JNJ4, A2APT9, A6NEL2, A6NP61, B1ASB6, B1WBS3, B2RXF5, F6WEQ6, O15015, O43918, O88282, O88286, O95785, P98168, P98169, Q2M3G4, Q2MHN3, Q2QGD7, Q3U1J1, Q3U381, Q497V6, Q5SW24, Q5SXM2, Q6YND2, Q6ZMQ8, Q6ZMY3, Q7TN08, Q7TSX9, Q80SU3, Q80YE4, Q811H0, Q8BG26, Q8BZW2, Q8C8V1, Q8IX07, Q8IY92, Q8N143, Q8N1G0, Q8NC74, Q8TBE0

Diamond homologs: A1YEP8, A1YEQ3, A1YEV9, A1YFW2, A1YFW6, A1YG26, A1YG48, A1YG60, A1YGJ4, A1YGK6, A2T6E3, A2T6V8, A2T6W2, A2T712, A2T736, A2T7D2, A2T7D7, A2T7F2, A2T7F4, A2T7L7, A2T812, A6QNZ0, A6QPT6, B2KFW1, O14709, O14771, O14978, O15535, O43309, O60304, O95125, P10073, P17022, P17028, P17029, P17040, P28698, P49910, P51815, P59923

SIGNOR signaling

0 interactions.

Disease & clinical

Clinical variants and AI predictions

ClinVar

165 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	5
Likely pathogenic	0
Uncertain significance	137
Likely benign	15
Benign	4

Top pathogenic / likely-pathogenic (5)

Variant ID	HGVS	Classification
1677001	NM_032805.3(ZSCAN10):c.2050del (p.His684fs)	Pathogenic
1677241	NM_032805.3(ZSCAN10):c.1250C>A (p.Ser417Ter)	Pathogenic
3335915	NM_032805.3(ZSCAN10):c.1456C>T (p.Gln486Ter)	Pathogenic
3335916	NM_032805.3(ZSCAN10):c.1112del (p.Pro371fs)	Pathogenic
3393116	NM_032805.3(ZSCAN10):c.598_602del (p.Pro200fs)	Pathogenic

SpliceAI

995 predictions. Top by Δscore:

Variant	Effect	Δscore
16:3090644:ATCC:A	acceptor_loss	1.0000
16:3090646:CCTG:C	acceptor_loss	1.0000
16:3092047:A:AC	donor_gain	1.0000
16:3092048:C:CC	donor_gain	1.0000
16:3092048:CTG:C	donor_gain	1.0000
16:3090645:TC:T	acceptor_gain	0.9900
16:3090646:CC:C	acceptor_gain	0.9900
16:3090647:C:CC	acceptor_gain	0.9900
16:3090648:T:A	acceptor_loss	0.9900
16:3092016:AGT:A	donor_gain	0.9900
16:3092597:T:TA	donor_gain	0.9900
16:3092607:C:A	donor_gain	0.9900
16:3099189:CCA:C	donor_gain	0.9900
16:3099189:CCACT:C	donor_gain	0.9900
16:3090655:C:CT	acceptor_gain	0.9800
16:3092018:T:TA	donor_gain	0.9800
16:3092027:T:TA	donor_gain	0.9800
16:3092054:T:A	donor_gain	0.9800
16:3092565:C:CA	donor_gain	0.9800
16:3092592:C:CT	donor_gain	0.9800
16:3092593:C:CT	donor_gain	0.9800
16:3099183:AACTC:A	donor_loss	0.9800
16:3099184:ACT:A	donor_loss	0.9800
16:3099185:CT:C	donor_loss	0.9800
16:3099186:TCA:T	donor_loss	0.9800
16:3099189:C:CG	donor_loss	0.9800
16:3099205:C:CT	donor_gain	0.9800
16:3099206:T:TT	donor_gain	0.9800
16:3090644:ATC:A	acceptor_gain	0.9700
16:3091706:C:CT	donor_gain	0.9700

AlphaMissense

5086 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
16:3089151:G:C	F706L	0.999
16:3089151:G:T	F706L	0.999
16:3089153:A:G	F706L	0.999
16:3089337:G:C	F644L	0.999
16:3089337:G:T	F644L	0.999
16:3089339:A:G	F644L	0.999
16:3089421:G:C	F616L	0.999
16:3089421:G:T	F616L	0.999
16:3089423:A:G	F616L	0.999
16:3089505:G:C	F588L	0.999
16:3089505:G:T	F588L	0.999
16:3089507:A:G	F588L	0.999
16:3089124:G:C	H715Q	0.998
16:3089124:G:T	H715Q	0.998
16:3089152:A:G	F706S	0.998
16:3089208:G:C	H687Q	0.998
16:3089208:G:T	H687Q	0.998
16:3089235:G:C	F678L	0.998
16:3089235:G:T	F678L	0.998
16:3089237:A:G	F678L	0.998
16:3089338:A:G	F644S	0.998
16:3089382:G:C	H629Q	0.998
16:3089382:G:T	H629Q	0.998
16:3089394:A:C	H625Q	0.998
16:3089394:A:T	H625Q	0.998
16:3089396:G:C	H625D	0.998
16:3089396:G:T	H625N	0.998
16:3089422:A:G	F616S	0.998
16:3089506:A:G	F588S	0.998
16:3089589:G:C	F560L	0.998

dbSNP variants (sampled 300 via entrez): RS1000119185 (16:3095802 T>C,G), RS1000198281 (16:3098650 A>C,G), RS1000211429 (16:3100650 T>A,C), RS1000355944 (16:3095547 G>C), RS1000378431 (16:3093667 T>C,G), RS1000410703 (16:3101254 G>A,C), RS1000792880 (16:3089912 C>T), RS1000816541 (16:3095335 G>A), RS1000846730 (16:3089623 C>G,T), RS1001675247 (16:3091207 G>A), RS1001678467 (16:3098596 G>A), RS1001812904 (16:3096953 C>A,T), RS1002117107 (16:3097216 C>G,T), RS1002156967 (16:3090964 G>A), RS1002223605 (16:3094175 G>A)

Disease associations

OMIM: gene MIM:618365 | disease phenotypes: MIM:620910

GenCC curated gene-disease

Disease	Classification	Inheritance
otofacial neurodevelopmental syndrome	Strong	Autosomal recessive

Mondo (2): sensorineural hearing loss disorder (MONDO:0020678), otofacial neurodevelopmental syndrome (MONDO:0975705)

Orphanet (0):

HPO phenotypes

33 total (30 of 33 shown, HPO-id order):

HPO	Term
HP:0000007	Autosomal recessive inheritance
HP:0000028	Cryptorchidism
HP:0000054	Micropenis
HP:0000175	Cleft palate
HP:0000218	High palate
HP:0000286	Epicanthus
HP:0000297	Facial hypotonia
HP:0000324	Facial asymmetry
HP:0000358	Posteriorly rotated ears
HP:0000365	Hearing impairment
HP:0000369	Low-set ears
HP:0000385	Small earlobe
HP:0000396	Overfolded helix
HP:0000407	Sensorineural hearing impairment
HP:0000431	Wide nasal bridge
HP:0000494	Downslanted palpebral fissures
HP:0000505	Visual impairment
HP:0000718	Aggressive behavior
HP:0000729	Autistic behavior
HP:0000733	Motor stereotypy
HP:0001256	Mild intellectual disability
HP:0001270	Motor delay
HP:0002342	Moderate intellectual disability
HP:0002591	Polyphagia
HP:0003577	Congenital onset
HP:0003623	Neonatal onset
HP:0008551	Microtia
HP:0009900	Unilateral deafness
HP:0010864	Severe intellectual disability
HP:0011236	Angulated antihelix

GWAS associations

0 associations (top):

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

16 total (human), top 16 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
entinostat	increases expression, affects cotreatment	2
Phenylmercuric Acetate	decreases expression, affects cotreatment	2
Valproic Acid	affects expression, increases methylation	2
aristolochic acid I	increases expression	1
sodium arsenite	increases expression	1
aflatoxin B2	increases methylation	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	affects cotreatment, increases expression, decreases expression	1
dorsomorphin	affects cotreatment, increases expression, decreases expression	1
Resveratrol	affects cotreatment, decreases expression	1
Arsenic	affects methylation	1
Benzo(a)pyrene	increases methylation	1
Bucladesine	affects cotreatment, increases expression	1
Estradiol	increases expression, affects cotreatment	1
Plant Extracts	decreases expression, affects cotreatment	1
Medroxyprogesterone Acetate	affects cotreatment, increases expression	1
Antirheumatic Agents	decreases expression	1

Cellosaurus cell lines

2 cell lines: 2 induced pluripotent stem cell

First 10 cell lines (id-ordered, not curated):

Cellosaurus	Name	Category	Sex
CVCL_LI32	A-iPSC-ZSCAN10-3	Induced pluripotent stem cell	Male
CVCL_LI33	A-iPSC-ZSCAN10-7	Induced pluripotent stem cell	Male

Clinical trials (associated diseases)

89 trials via MONDO — disease-level, not drug-specific.

Trial	Phase	Status	Title
NCT01655212	PHASE3	TERMINATED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment in a Randomized Controlled Trial
NCT02005822	PHASE3	COMPLETED	Congenital Cytomegalovirus: Efficacy of Antiviral Treatment
NCT03374514	PHASE3	UNKNOWN	Cochlear Electrical Impedance and the Effect of Topical Dexamethasone on Cochlear Implant Surgery
NCT02497690	PHASE2	COMPLETED	Effectiveness of Therapy Via Telemedicine Following Cochlear Implants
NCT03107871	PHASE2	ACTIVE_NOT_RECRUITING	Randomized Controlled Trial of Valganciclovir for Cytomegalovirus Infected Hearing Impaired Infants
NCT04120116	PHASE2	COMPLETED	FX-322 in Adults With Stable Sensorineural Hearing Loss
NCT05061758	PHASE2	WITHDRAWN	A Trial of LY3056480 in Patients With SNLH
NCT07364747	PHASE2	RECRUITING	Protective Effect of Acetylcysteine Against Cisplatinum-Induced Ototoxicity: A Randomized Controlled Trial
NCT02259595	PHASE1	COMPLETED	Study to Determine the Safety, Tolerability, and Pharmacokinetic Profile of HPN-07 and HPN-07 Plus NAC
NCT02693704	PHASE2/PHASE3	COMPLETED	Evaluation of a Binaural Spatialization Method for Hearing Aids
NCT02882477	PHASE2/PHASE3	UNKNOWN	Treatment of Wolfram Syndrome Type 2 With the Chelator Deferiprone and Incretin Based Therapy
NCT01267994	PHASE1/PHASE2	COMPLETED	A Clinical Trial of Anakinra for Steroid-Resistant Autoimmune Inner Ear Disease
NCT01902914	PHASE1/PHASE2	UNKNOWN	Effectiveness of P02 Digital Hearing Aids
NCT02038972	PHASE1/PHASE2	COMPLETED	Safety of Autologous Stem Cell Infusion for Children With Acquired Hearing Loss
NCT02616172	PHASE1/PHASE2	SUSPENDED	Autologous Bone Marrow Harvest and Transplant for Sensorineural Hearing Loss
NCT03616223	PHASE1/PHASE2	COMPLETED	FX-322 in Sensorineural Hearing Loss
NCT04129775	PHASE1/PHASE2	COMPLETED	OTO-413 in Subjects With Speech-in-Noise Hearing Impairment
NCT04462198	PHASE1/PHASE2	COMPLETED	Phase I/IIa Study Evaluating Safety and Efficacy of an Intratympanic Dose of PIPE-505 in Subjects With Hearing Loss
NCT07032038	PHASE1/PHASE2	NOT_YET_RECRUITING	First In Human Randomised Trial of Rincell-1 in Adults With a Cochlear Implant
NCT06025097	EARLY_PHASE1	COMPLETED	Intra-Tympanic Steroid With PRP Combination in Sensorineural Hearing Loss and Tinnitus.
NCT06707389	EARLY_PHASE1	NOT_YET_RECRUITING	Autologous Blood Monocyte Vesicles for the Treatment of Sudden Deafness
NCT07472023	EARLY_PHASE1	ENROLLING_BY_INVITATION	Regenerative Medicine and Stem Cell-Based Interventions for Inner Ear Trauma, Tinnitus, and Sensorineural Hearing Loss
NCT00023036	Not specified	COMPLETED	Clinical and Genetic Analysis of Enlarged Vestibular Aqueducts
NCT00023049	Not specified	COMPLETED	Genetic Analysis of Hereditary Disorders of Hearing and Balance
NCT00261768	Not specified	COMPLETED	Efficacy of Digital Noise Reduction Strategies: A Hearing Aid Trial
NCT00589511	Not specified	COMPLETED	Nucleus Freedom Cochlear Implant System Pediatric Post-approval Study
NCT00678899	Not specified	COMPLETED	Evaluation of the Nucleus Hybrid™ L24 Cochlear Implant System
NCT00787189	Not specified	COMPLETED	Study of Low Level Laser Therapy and Word Recognition in Hearing Impaired Individuals
NCT01184248	Not specified	COMPLETED	The Effect of Sound Stimulation on Pure-tone Hearing Threshold
NCT01434446	Not specified	COMPLETED	The Effect of Sound Stimulation on Hearing Ability
NCT01749592	Not specified	COMPLETED	Single-sided Deafness and Cochlear Implants
NCT01781039	Not specified	COMPLETED	Investigation of Anatomical Correlates of Speech Discrimination
NCT02082431	Not specified	COMPLETED	Determine the Incidence of Long QT Amongst a Large Cohort of Subjects Diagnosed With Unilateral or Bilateral Sensorineural Hearing Loss.
NCT02093806	Not specified	UNKNOWN	Clinical Applications of Round Window Imaging Anatomy in Cochlear Implant Surgery
NCT02252601	Not specified	UNKNOWN	Evaluation of the High Frequency Digit Triplet Test in Cystic Fibrosis
NCT02584361	Not specified	UNKNOWN	Cochlear Implant and Vestibular Function.
NCT02638883	Not specified	COMPLETED	Implantation of the Cochlear™ Nucleus® Hybrid S Round Window (S-RW) in Adults
NCT02689349	Not specified	COMPLETED	Esteem New Subject Enrollment Post Approval Study
NCT02698787	Not specified	COMPLETED	Fundamental Asynchronous Stimulus Timing Sound Coding Study
NCT02798783	Not specified	COMPLETED	Enlarged Vestibular Aqueduct Registry